The Technical Analyst
Gamida Cell Ltd [GMDA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Gamida Cell Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.00% $0.0327
America/New_York / 5 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.34 mill |
| EPS: | -0.820 |
| P/E: | -0.0400 |
| Earnings Date: | Mar 24, 2024 |
| SharesOutstanding: | 132.64 mill |
| Avg Daily Volume: | 9.98 mill |
| RATING 2024-04-05 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Neutral | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0400 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0400 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0251 - 0.0549 ( +/- 268.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-31 | Moch Kenneth I | Buy | 200 000 | Ordinary Shares |
| 2024-01-31 | Wills Stephen T | Buy | 200 000 | Ordinary Shares |
| 2024-01-31 | Tomasello Shawn | Buy | 200 000 | Ordinary Shares |
| 2024-01-31 | Adams Julian | Buy | 200 000 | Ordinary Shares |
| 2024-01-31 | Simantov Ronit | Buy | 480 319 | Ordinary Shares |
| INSIDER POWER |
|---|
| 94.76 |
| Last 90 transactions |
| Buy: 8 073 627 | Sell: 418 674 |
Forecast:
16:00 - $0.0349
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0349
Forecast 2: 16:00 - $0.0349
Forecast 3: 16:00 - $0.0349
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0327 (0.00% ) |
| Volume | 23.04 mill |
| Avg. Vol. | 9.98 mill |
| % of Avg. Vol | 230.77 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GMDA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $0.371 | N/A | Active |
|---|
GMDA
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-03-27 07:00:00 - Press Release
Gamida Cell Announces Commencement Of Restructuring Process Supported By Highbridge Capital Management
Company expected to receive significant new capital from highbridge to bolster the commercialization of allogeneic stem cell transplant omisirge ® (omidubicel-onlv)
2024-03-27 07:00:00 - Press Release
Gamida Cell Reports Fourth Quarter And Full-year 2023 Financial Results And Provides Company Update
Company announces commencement of restructuring process supported by highbridge capital management continued progress of launch of omisirge ® (omidubicel-onlv), with the delivery of six units in 2023, as well as significant transplant center onboarding company to host conference call today at 8:30 a.m. et boston, march 27, 2024 (globe newswire) -- gamida cell ltd.
2024-03-22 08:00:00 - Press Release
Gamida Cell To Report Fourth Quarter And Full-year 2023 Financial Results
Boston, march 22, 2024 (globe newswire) -- gamida cell ltd. (nasdaq: gmda), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended december 31, 2023 and provide an update on the company on wednesday, march 27, 2024.
2024-02-23 08:00:00 - Press Release
Gamida Cell Data Presented At The 2024 Tandem Meetings Of Astct® And Cibmtr®
Expanded access program (eap) data for omidubicel are consistent with phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with omisirge ® (omidubicel-onlv)
2024-01-29 06:00:00 - Press Release
Gamida Cell Actively Pursuing Strategic Alternatives
Boston, jan. 29, 2024 (globe newswire) -- gamida cell ltd. (nasdaq: gmda), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction. however, there can be no assurance that the company's strategic alternatives process will result in any such transaction.
Latest News
2024-03-27 11:16:51 - InvestorPlace
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Gamida Cell (NASDAQ: GMDA ) stock is falling hard on Wednesday after the clinical-stage biopharmaceutical company announced major changes to its business in its Q4 earnings report. This big news here is the company entering into a Restructuring Support Agreement (RSA) with funds managed by Highbridge Capital Management.
2024-03-22 08:00:00 - GlobeNewsWire
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024.
2024-01-17 08:00:00 - GlobeNewsWire
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it will present new data on its FDA approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings will take place virtually and in person at the Henry B. González Convention Center in San Antonio, Texas, February 21-24.
2023-11-20 08:00:00 - GlobeNewsWire
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.
2023-10-09 08:53:00 - Market Watch
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.
2023-08-14 19:02:02 - Seeking Alpha
Gamida Cell: The Treacherous Path To Profitability
Gamida Cell's approved therapy, Omisirge, shows faster neutrophil recovery and reduced infections in blood cancer patients compared to standard care. The long-term study of Omisirge includes a diverse patient population, improving its marketability. Cash headwinds continue to be a challenge, and their latest financial filings do not ease this uncertainty.
2023-06-09 10:57:17 - Zacks Investment Research
Gamida Cell (GMDA)'s Technical Outlook is Bright After Key Golden Cross
Gamida Cell Ltd. (GMDA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support.
2023-05-31 16:30:00 - Business Wire
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commercial Officer, will present corporate highlights at the upcoming Jefferies Healthcare Conference on June 8, 2023 at 9:30 a.m. ET. Ms. Korfin's presentation will include an overview of the company's corporate strategy and commercial strategy for Omisirge®. The webcast will be available on the “Invest.
2023-05-15 20:39:08 - Seeking Alpha
Gamida Cell Ltd. (GMDA) Q1 2023 Earnings Call Transcript
Gamida Cell Ltd. (NASDAQ:GMDA ) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President and CEO Michele Korfin - COO and Chief Commercial Officer Ronit Simantov - Chief Medical Officer and Scientific Officer Shai Lankry - CFO Conference Call Participants Edward Tenthoff - Piper Sandler Gil Blum - Needham & Company Vernon Bernardino - H.C.
2023-05-11 17:20:00 - Business Wire
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conferenc.